Log in
Register|
bebacrk ☆ India, 2026-02-12 06:14 (111 d 22:13 ago) Posting: # 24568 Views: 1,379 |
|
|
is open label study acceptable for Canada after implementation of ICH M13A guidelines. Outlier tests are acceptable? if so in full replicate design, if any subject found outlier in particular period for Cmax and AUC, is that subject data should be removed from perticulaer period or from all the periods when calculating pharmacokinetic and statistical analysis? Edit: Please follow the Forum’s Policy. [Helmut] |
|
Helmut ★★★   Vienna, Austria, 2026-02-12 10:03 (111 d 18:23 ago) @ bebacrk Posting: # 24569 Views: 1,202 |
|
|
Hi bebacrk, ❝ is open label study acceptable for Canada after implementation of ICH M13A guidelines. ❝ Outlier tests are acceptable? ❝ if so in full replicate design, if any subject found outlier in particular period for Cmax and AUC, is that subject data should be removed from perticulaer period or from all the periods when calculating pharmacokinetic and statistical analysis? — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png) Helmut Schütz ![[image]](https://static.bebac.at/img/CC by.png) The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
|
bebacrk ☆ India, 2026-02-12 10:53 (111 d 17:34 ago) @ Helmut Posting: # 24570 Views: 1,194 |
|
|
❝ ICH M13A does not cover replicate design (M13C will). Therefore, Section 2.3.5 of Health Canada’s guidance is still applicable. Thank you sir. yes agree sir. But in full replicate design if subject found outlier in particular period for Cmax and AUC parameters of Swr calculation, shall we remove that particular period data from PK & Statistical analysis or from entire study periods? can you please mention what are the scenarios we can fallow for Canada full replicate design to exclude the subject from pharmacokinetic and statistical analysis. Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut] |
|
Helmut ★★★ Vienna, Austria, 2026-02-13 11:33 (110 d 16:53 ago) @ bebacrk Posting: # 24573 Views: 1,076 |
|
|
Hi bebacrk, ❝ But in full replicate design if subject found outlier in particular period for Cmax and AUC parameters of Swr calculation, shall we remove that particular period data from PK & Statistical analysis or from entire study periods? ❝ can you please mention what are the scenarios we can fallow for Canada full replicate design to exclude the subject from pharmacokinetic and statistical analysis. The Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies of 2018 contains Section 2.3.5 about outliers. However, I was wrong above, saying ❝ ❝ […] Section 2.3.5 of Health Canada’s guidance is still applicable All sections of this guidance remain applicable […] with the exception of Section 2.3.5. In order to harmonise approaches, Section 2.3.5 is superseded by the ICH M13A guideline. (my emphasis)IMHO, that’s ambiguous at least. ICH M13A (no outlier assessment) deals only with 2×2 cross-over and parallel designs, whereas HC’s 2018 guidance also with replicate designs and reference-scaling for AUC. So does that mean that outlier assessment is not applicable for these studies (covered in the upcoming ICH M13C) as well?  Nothing is stated about outliers in the Supplement to the Concept Paper to ICH M13C of 2025. I don’t know whether the M13 EWG will discuss it at all. Currently in jurisdictions applying ABEL – except Chile and Brazil – it has to be demonstrated that the high variability of the reference is not caused by outliers. No outlier assessment has to be performed for RSABE (US FDA and China’s CDE). — Dif-tor heh smusma 🖖🏼 Довге життя Україна! Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
Ing. Helmut Schütz